Investigators: Drs. Angela Chen, Susan Cotter, Raymond Chu, Silvia Han, Catherine Heyman, Kristine Huang, Reena Patel, Dashaini Retnasothie, Ashley Nickell, Clinton Prestwich
Why It’s Important: Amblyopia is the medical term used when the vision in one eye is reduced because the eye is not being used properly. This happens because the brain is favoring one eye over the other. It is one of the most common causes of decreased vision in children and affects approximately two or three out of every 100 children.
Randomized clinical trials and prospective observational studies have shown improvement in visual acuity with spectacle correction (when there is uncorrected refractive error) followed by treatment with part-time patching or atropine eye drops. Although these treatments are effective, not all children reach 20/20 visual acuity; in fact, residual amblyopia (20/32 or worse) remains in many treated children.
Based on the prevalence of residual amblyopia that remains with current part-time patching treatment and the challenges of compliance with patching, new treatments for amblyopia are needed, particularly those that can be visually unobtrusive and that do not overly interfere with the vision of the fellow eye.
A new treatment for amblyopia is binocular anti-suppression game therapy. This involves playing the dig rush game on an iPad while wearing red/green glasses. Recently, some studies found this treatment works very well in a number of children and adults with amblyopia. The present study is being done to compare this binocular game treatment with spectacles alone.
Description: This study is a multicenter randomized clinical trial designed to evaluate the effectiveness of 1 hour per day, 5 days per week of binocular game play on an iPad with spectacles alone in 200 children 4 to <13 years of age with amblyopia in one eye.
Status: ACTIVELY ENROLLING
Study Contact: Study Coordinator, Ms. Susan Parker: 714.463.7580 or firstname.lastname@example.org
Funding and Additional Information: National Institutes of Health / National Eye Institute: U10 EY11751; Registered at: ClinicalTrials.gov - Identifier: NCT02983552